Long-term survival and cure fraction in patients with advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world data.
2/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
1581 patients treated by atezolizumab-bevacizumab (median follow-up: 34.
I · Intervention 중재 / 시술
atezolizumab-bevacizumab (median follow-up: 34
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
In 1187 patients meeting IMbrave150 criteria, long-term survival reached 15.4% (95%CI:10.6-18.5%) and cure fraction 9.1% (95%CI:7.3-11.4%).ALBI score, and hepatitis C predicted long-term survival and albumin and hepatitis C predicted cure. [CONCLUSION] Across trials and real-world data, ICIs combinations achieve long-term survival in 10-15% of advanced HCC patients, with cure fractions of 7-9%.
OpenAlex 토픽 ·
Hepatocellular Carcinoma Treatment and Prognosis
Cancer Immunotherapy and Biomarkers
Cholangiocarcinoma and Gallbladder Cancer Studies
[BACKGROUND & AIMS] Immune checkpoint inhibitors (ICIs) can induce long-term survival and even cancer cure in several cancers.
- 95% CI 8.5-18.6
- 추적기간 30 months
APA
Claudia Campani, Ju Hyun Shim, et al. (2026). Long-term survival and cure fraction in patients with advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world data.. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.CCR-25-4943
MLA
Claudia Campani, et al.. "Long-term survival and cure fraction in patients with advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world data.." Clinical cancer research : an official journal of the American Association for Cancer Research, 2026.
PMID
42008357 ↗
Abstract 한글 요약
[BACKGROUND & AIMS] Immune checkpoint inhibitors (ICIs) can induce long-term survival and even cancer cure in several cancers. Mixture cure models (MCMs) estimate the fraction of long-term survivors and cured patients but have not been applied in HCC.
[METHODS] We identified phase 3 randomized trials of first-line ICI in advanced HCC with mature follow-up (≥30 months) and analyzed a cohort of HCC patients treated with atezolizumab-bevacizumab. After reconstructing Kaplan-Meier curves, MCMs estimated long-term survivors' fraction (overall survival, OS) and cure fractions (progression-free survival, PFS).
[RESULTS] In HIMALAYA (median follow-up of 60 months), long-term survival was 12.8% (95%CI:8.5-18.6%) with durvalumab-tremelimumab versus 5.2% (95%CI:2.6-10.2%) with sorafenib; cure fraction was not assessable.In CheckMate9DW (median follow-up: 35.2 month), long-term survival was 8.7% (95%CI:0.2-81.3%) versus 4.1% (95%CI:0.1-66.1%) and cure fractions were 17.8% (95%CI:12.0-25.8%) versus 3.5% (95%CI:0.7-16.7%) for nivolumab-ipilimumab and sorafenib/lenvatinib respectively with long-term OS estimates remaining exploratory due to limited late numbers at risk.In RATIONALE-301, long-term survival was 25.2% (95%CI:19.2-32.2) with tislelizumab versus 15.4% (95%CI: 10.0-22.8) with sorafenib. IMbrave150 trial was not analyzed due to insufficient follow-up (15.6 months). Among a clinical cohort of 1581 patients treated by atezolizumab-bevacizumab (median follow-up: 34.7 months), long-term survival was 12.3% (95%CI:9.3-16.1%) and cure fraction 7.9% (95%CI:6.3-9.8%). In 1187 patients meeting IMbrave150 criteria, long-term survival reached 15.4% (95%CI:10.6-18.5%) and cure fraction 9.1% (95%CI:7.3-11.4%).ALBI score, and hepatitis C predicted long-term survival and albumin and hepatitis C predicted cure.
[CONCLUSION] Across trials and real-world data, ICIs combinations achieve long-term survival in 10-15% of advanced HCC patients, with cure fractions of 7-9%.
[METHODS] We identified phase 3 randomized trials of first-line ICI in advanced HCC with mature follow-up (≥30 months) and analyzed a cohort of HCC patients treated with atezolizumab-bevacizumab. After reconstructing Kaplan-Meier curves, MCMs estimated long-term survivors' fraction (overall survival, OS) and cure fractions (progression-free survival, PFS).
[RESULTS] In HIMALAYA (median follow-up of 60 months), long-term survival was 12.8% (95%CI:8.5-18.6%) with durvalumab-tremelimumab versus 5.2% (95%CI:2.6-10.2%) with sorafenib; cure fraction was not assessable.In CheckMate9DW (median follow-up: 35.2 month), long-term survival was 8.7% (95%CI:0.2-81.3%) versus 4.1% (95%CI:0.1-66.1%) and cure fractions were 17.8% (95%CI:12.0-25.8%) versus 3.5% (95%CI:0.7-16.7%) for nivolumab-ipilimumab and sorafenib/lenvatinib respectively with long-term OS estimates remaining exploratory due to limited late numbers at risk.In RATIONALE-301, long-term survival was 25.2% (95%CI:19.2-32.2) with tislelizumab versus 15.4% (95%CI: 10.0-22.8) with sorafenib. IMbrave150 trial was not analyzed due to insufficient follow-up (15.6 months). Among a clinical cohort of 1581 patients treated by atezolizumab-bevacizumab (median follow-up: 34.7 months), long-term survival was 12.3% (95%CI:9.3-16.1%) and cure fraction 7.9% (95%CI:6.3-9.8%). In 1187 patients meeting IMbrave150 criteria, long-term survival reached 15.4% (95%CI:10.6-18.5%) and cure fraction 9.1% (95%CI:7.3-11.4%).ALBI score, and hepatitis C predicted long-term survival and albumin and hepatitis C predicted cure.
[CONCLUSION] Across trials and real-world data, ICIs combinations achieve long-term survival in 10-15% of advanced HCC patients, with cure fractions of 7-9%.
같은 제1저자의 인용 많은 논문 (3)
- New player in inflammation-driver liver carcinogenesis: pirin on fire!
- Molecularly guided therapies for advanced primary liver cancers refractory to systemic treatment: Results from the 2025 French Genomic Medicine Initiative.
- The "A-B-C" Classification Reveals Outcome Trajectories in Patients With Hepatocellular Carcinoma Under Atezolizumab/Bevacizumab.